CRISPR Diagnostics Market (2026-2036)

The CRISPR diagnostics market covers assay kits and consumables, instruments and readers, the enzymes, guide RNA and reagents used to build such assays, and the analysis software and services supplied around them, across Cas12, Cas13, Cas9 and other nuclease classes, in amplification-coupled and amplification-free detection formats. The growth of this market is driven by detection that requires no thermocycler, by nuclease classes that sit outside the contested foundational patent position, by acquisition of developers into point-of-care diagnostics companies, and by research and reagent demand ahead of clinical adoption.

A CRISPR assay competes against multiplex polymerase chain reaction, which is cleared, reimbursed and already installed in clinical laboratories, so it has to offer something that polymerase chain reaction cannot. Detection without thermal cycling, in one step and at or near ambient temperature, is the property that polymerase chain reaction does not have, and it matters at the point of care and in settings without laboratory infrastructure rather than in a laboratory that already runs analysers.

The United States Court of Appeals for the Federal Circuit decided The Regents of the University of California v. Broad Institute, Inc., No. 22-1653, on 12 May 2025, vacating and remanding the interference to the Patent Trial and Appeal Board on the basis that the Board legally erred by conflating the distinct legal standards for conception and reduction to practice, while affirming the finding that the first University of California provisional application lacked written description and dismissing the Broad cross-appeal on claim construction as moot. The Patent Trial and Appeal Board reaffirmed on 26 March 2026 that the Broad Institute holds priority for the single-guide CRISPR-Cas9 system for editing eukaryotic genes, finding that the University of California had not met its burden of showing its inventors conceived the invention before the Broad reduction to practice and rejecting the derivation claim, which preserves 13 issued Broad patents and one application against 14 University of California applications in that interference, and leaves Sigma-Aldrich and ToolGen able to renew their own challenges. That interference concerns the single-guide system for editing eukaryotic genes, which is a therapeutic and research claim, while diagnostic assays depend on the collateral cleavage activity of Cas12 and Cas13 enzymes that sit in different patent families, so the licensing exposure of a diagnostics developer is not the one the eleven-year dispute describes.

A CRISPR diagnostic uses a programmed nuclease to recognise a target nucleic acid sequence and, on recognition, to cleave reporter molecules in the reaction, which produces a signal read as fluorescence, as a line on a lateral flow strip or as an electrochemical change. The specificity comes from a guide RNA that can be redesigned for a new target in days rather than from an antibody or a probe set that has to be developed, which is the property that makes the approach interesting for emerging pathogens. A laboratory can therefore convert an assay to a new variant within an outbreak rather than after it, which is the practical claim the technology makes against every established method.

Competition with multiplex polymerase chain reaction defines what this market can be. Polymerase chain reaction is cleared for clinical use, reimbursed through procedure codes, and runs on analysers already placed in clinical laboratories, so a CRISPR assay offering equivalent sensitivity in the same setting has nothing to displace it with. Detection in one step without thermal cycling at or near ambient temperature is the property polymerase chain reaction does not have, and it is useful where there is no thermocycler, no cold chain and no laboratory.

Most CRISPR assays described to date nonetheless include an amplification step, using recombinase polymerase amplification or loop-mediated isothermal amplification before the nuclease reaction, because detecting a handful of target molecules without amplification is difficult. An assay that amplifies isothermally has still removed the thermocycler, but it has added a second enzymatic step and the contamination risk that comes with amplification, so the practical simplicity is less than the concept promises.

Amplification-free detection is where the technology would become genuinely distinct, since a single-step reaction read at ambient temperature could be packaged as a disposable test used outside any laboratory. Approaches that achieve it rely on signal cascades, enzyme concentration or improved reporter chemistry rather than on target amplification. That segment carries the fastest growth in this market and the smallest current revenue, because the sensitivity required for clinical claims has been reached in a limited number of targets.

The United States Court of Appeals for the Federal Circuit decided The Regents of the University of California v. Broad Institute, Inc., No. 22-1653, on 12 May 2025, vacating and remanding the interference to the Patent Trial and Appeal Board on the basis that the Board legally erred by conflating the distinct legal standards for conception and reduction to practice, while affirming the finding that the first University of California provisional application lacked written description and dismissing the Broad cross-appeal on claim construction as moot. The Patent Trial and Appeal Board reaffirmed on 26 March 2026 that the Broad Institute holds priority for the single-guide CRISPR-Cas9 system for editing eukaryotic genes, finding that the University of California had not met its burden of showing its inventors conceived the invention before the Broad reduction to practice and rejecting the derivation claim, which preserves 13 issued Broad patents and one application against 14 University of California applications in that interference, and leaves Sigma-Aldrich and ToolGen able to renew their own challenges. Eleven years of interference proceedings over a single foundational question, with the possibility of further appeal and with Sigma-Aldrich and ToolGen now able to renew challenges, establishes how long priority in this field takes to settle rather than settling it.

The contested claim concerns the single-guide CRISPR-Cas system for editing eukaryotic genes, which is a therapeutic and research use. Diagnostic assays rely on the collateral, non-specific cleavage that Cas12 and Cas13 enzymes perform after recognising their target, and those enzymes and that mechanism sit in different patent families from the single-guide Cas9 claim. A diagnostics developer licensing Cas12a therefore faces a different and less prominent licensing position than the dispute suggests.

OraSure Technologies, Inc. completed the acquisition of Sherlock Biosciences, Inc. with effect from 19 December 2024, as reported in the Form 8-K/A filed with the Securities and Exchange Commission. Placing a CRISPR diagnostics developer inside a company whose business is point-of-care testing and self-collection rather than inside a laboratory instrument company indicates where the commercial value was judged to lie, since the channel rather than the enzyme is what a point-of-care test requires.

Revenue in this market currently comes predominantly from enzymes, guide RNA and reagents sold to researchers and assay developers rather than from clinical tests, which is the position of a technology that has demonstrated feasibility and not yet established clinical utility at scale. Reagent revenue grows with the number of groups working on the approach, so it responds to research funding rather than to clinical adoption and will be displaced in share as kits reach clinical use. That composition is itself the clearest measure of how early this market is, since a technology in routine clinical use sells tests rather than components. A buyer assessing this market should therefore read the product mix as a maturity indicator alongside the growth rate, because a market whose revenue is mostly reagents has not yet proved the thing its growth rate assumes.

An assay supplied as a laboratory developed test operates under enforcement discretion in the United States following the rescission of the 2024 rule on laboratory developed tests, while a test intended for over-the-counter or point-of-care use outside a laboratory requires clearance or authorisation on its own merits. The second route is where the technology has its advantage and where the evidence requirement is highest, which is the central tension in commercialising it.

Non-clinical applications account for a meaningful share of near-term revenue and are often overlooked. Detection of plant pathogens, genetically modified content in food, foodborne bacteria and environmental organisms uses the same chemistry without the clinical evidence requirement or the reimbursement dependency, and the buyers are testing laboratories that purchase on cost per sample. That demand is available now rather than after a clinical claim is established. Validation work completed for those applications also transfers partially to a later clinical submission, so the revenue and the regulatory groundwork accumulate together rather than competing for the same budget.